Outcomes of basiliximab vs alemtuzumab induction in kidney allograft recipients with matched immunological Profiles: A retrospective cohort study

Figure 1 Flow chart showing the selection of kidney transplant recipients who received alemtuzumab or basiliximab induction between 2014 and 2019 at two transplant centers. Exclusions were based on predefined criteria. Propensity score matching was performed using recipient age, donor type, cold ischemia time (< 24 hours or > 24 hours), year of transplantation, age group (≥ 60 years vs < 60 years), human leucocyte antigen-DR mismatch, and percentage of panel reactive antibody: (1) Cold ischemia time; (2) Human leucocyte antigen; and (3) Royal Liverpool Hospital. CIT: Cold ischemia time; HLA: Human leucocyte antigen; PRA: Panel reactive antibody; RLH: Royal Liverpool Hospital.